In light of strong TIM-3 expression being predictive of a good anti-PD-(L)1 immunotherapy response in a cohort of 30 head and neck cancers patients [39] and of anti-TIM-3 antibodies being evaluated alone or in combination with anti-PD-(L)1 therapy in several phase 1 trials [40], our own findings, should they be confirmed by larger multicentric studies, support the rational for testing immunotherapy adjuvant treatments specifically in patients that fail to achieve a pCR. The gene discussed is HAVCR2; the disease is head and neck cancer.